Skip to content

Advertisement

  • Research
  • Open Access

Clinical results of proton beam therapy for advanced neuroblastoma

  • 1,
  • 1,
  • 1,
  • 4,
  • 2,
  • 1,
  • 2,
  • 1,
  • 1,
  • 3,
  • 3 and
  • 1Email author
Radiation Oncology20138:142

https://doi.org/10.1186/1748-717X-8-142

©  Oshiro et al.; licensee BioMed Central Ltd. 2013

  • Received: 18 January 2013
  • Accepted: 1 June 2013
  • Published:

Abstract

Purpose

To evaluate the efficacy of proton beam therapy (PBT) for pediatric patients with advanced neuroblastoma.

Methods

PBT was conducted at 21 sites in 14 patients with neuroblastoma from 1984 to 2010. Most patients were difficult to treat with photon radiotherapy. Two and 6 patients were classified into stages 3 and 4, respectively, and 6 patients had recurrent disease. Seven of the 8 patients who received PBT as the initial treatment were classified as the high risk group. Twelve patients had gross residual disease before PBT and 2 had undergone intraoperative radiotherapy before PBT. Five patients received PBT for multiple sites, including remote metastases. Photon radiotherapy was used in combination with PBT for 3 patients. The PBT doses ranged from 19.8 to 45.5 GyE (median: 30.6 GyE).

Results

Seven patients are alive with no evidence of disease, 1 is alive with disease progression, and 6 died due to the tumor. Recurrence in the treatment field was not observed and the 3-year locoregional control rate was 82%. Severe acute radiotoxicity was not observed, but 1 patient had narrowing of the aorta and asymptomatic vertebral compression fracture at 28 years after PBT, and hair loss was prolonged in one patient.

Conclusion

PBT may be a better alternative to photon radiotherapy for children with advanced neuroblastoma, and may be conducted safely for patients with neuroblastoma that is difficult to manage using photon beams.

Keywords

  • Neuroblastoma
  • Proton therapy
  • Radiotherapy
  • Late toxicity
  • Pediatrics

Introduction

Neuroblastoma is the most common extracranial solid tumor in children. Half of newly diagnosed patients present with high risk disease that is widely metastatic and has large and invasive lesions in the advanced stage. Aggressive treatment is conducted in these cases because they are highly sensitive to radiotherapy and chemotherapy. However, despite recent progress with systemic therapy, the treatment outcome in high risk neuroblastoma is poor [1–5]. Advanced neuroblastoma also often recurs and the prognosis after recurrence is extremely poor [6–8], with Garaventa et al. finding survival rates of only 6.6% and 1.5% in patients with progression and relapse disease [7]. Recently, the superiority of the dose distribution in proton beam therapy (PBT) has been shown compared to the photon dose distribution especially in children [9–13]. However, to our knowledge, there are few reports on clinical outcomes after PBT. [14] We have mainly treated patients with advanced high risk neuroblastoma or recurrent disease using PBT since 1984. Herein, we report a retrospective review of the outcome and toxicity in these patients.

Methods

Patients

Fourteen patients with neuroblastoma received PBT at 21 sites from 1984 to 2010 at our institute. The patient characteristics are shown in Table 1. The patients were 6 boys and 8 girls with a median age of 3 years old (range 1 to 6 years old). PBT was conducted because photon beam radiotherapy was difficult due to a large irradiation area involving normal organs such as the liver, heart, and gastrointestinal tract for 8 patients (Nos. 1–3, 6, 7, 12–14), and because PBT was considered a better option for reduction of the dose to the eyes for 4 patients with orbital, paranasal sinus and skull base disease (Nos. 4, 8, 9, 11). The other 2 patients (Nos. 5, 10) received PBT because of the wishes of their families. All patients had received chemotherapy before PBT.[2] Eight patients received PBT as initial treatment, including two with Stage 3 and six with Stage 4 disease classified by the International Neuroblastoma Staging System (INSS). The other 6 patients received PBT for recurrent disease. Twelve patients of the 14 had gross residual disease. Eleven patients were classified as high risk (i.e. those with stage 4 disease aged older than 1 year at diagnosis or those with stage 3 MYCN-amplified tumors), 2 with recurrent disease were intermediate risk (i.e. stage 3 disease aged older than 1 year with favorable histology and MYCN-non-amplified tumors), and insufficient biological and histological data were available to determine the risk group in 1 patient diagnosed in 1982 according to the international neuroblastoma risk group (INRG) staging system[15]. The treatment site was the abdomen and pelvis in 9 cases, head and neck in 7, thorax in 2, paravertebra in 1, acetabulum in 1, and skull in 1. Five patients received PBT at multiple sites for primary and metastatic lesions. Photon radiotherapy was used in combination with PBT for 3 patients for lymph nodes and distant metastases. Intraoperative radiotherapy (IORT) had undergone for the recurrent disease in 2 patients.
Table 1

Background of 14 patients treated with proton beam therapy

Patient No

Age at PBT

Risk

INSS stage

Site

Surgery

Gross residual disease at PBT

PBT dose (GyE)

Port No.

Sedation

Respiratory gating

X-ray

1

1

Unknown

3

upper abdomen

open biopsy

Yes

28.6

1

yes

no

none

2

2

High

4

retroperitoneum

complete resection

No

19.8

1

yes

yes

Photon for femoral bone

3

6

High

3

mediastinum

None

Yes

30.6

3

no

yes

Electron for axillary LN and skull

4

5

High

3

Paranasal sinus

None

No

19.8

2

no

no

Photon for whole neck LN

5

3

High

4

paravertebra

partial removal

Yes

39.6

1

no

yes

none

6

3

High

4

retroperitoneum

partial removal

Yes

30.6

2

no

yes

none

7

5

High

4

retroperitoneum

partial removal

Yes

30.6

2

no

yes

none

skull base

None

No

19.8

2

no

8

2

High

4

retroperitoneum

partial removal

No

19.8

2

yes

yes

none

skull

None

Yes

19.8

1

no

orbit

None

Yes

19.8

1

no

9

3

High

R*

orbit

none

Yes

43.7

1

yes

no

Cobalt for neck LN

10

6

High

R

paravertebra

None

Yes

45.5

2

no

no

none

mediastinal node

None

Yes

45.5

2

yes

11

6

High

R

skull base

None

Yes

33.7

2

no

no

none

occipital bone

None

Yes

33.7

2

no

12

2

Intermediate

R

retroperitoneum

none

Yes

41.4

2

yes

yes

Post IORT 12Gy

13

2

High

R

retroperitoneum

None

Yes

41.4

2

yes

yes

Post IORT 12Gy

    

paraaorta LN†

None

Yes

30.6

2

 

yes

none

14

6

Intermediate

R

supraclavicular LN

None

Yes

30.6

1

no

no

    

acetabulum

None

Yes

30.6

2

 

no

*R: recurrent disease, †LN: lymph nodes.

Proton therapy

Before treatment, CT images for PBT planning were obtained at intervals of 2–5 mm in the treatment position. The interval was determined based on the patient’s age, height and treatment site. For 10 patients with pelvic and thoracic disease, the CT image was obtained during the end expiratory phase using a respiratory gating system, as described previously [16, 17]. The gross tumor volume (GTV) was defined as the tumor volume after remission induction chemotherapy for a primary tumor and the tumor volume before PBT for a recurrent tumor. The clinical target volume (CTV) was defined as the GTV plus a 1.5-cm margin and the PTV was defined as the CTV plus a 0.5- to 0.7-cm margin, in principle; however, the balance between toxicity and treatment effect was also taken into account in determining the CTV. Sedatives were administered for 5 patients aged 1 to 3 for planning CT and treatment.

Between 1994 and 2000, PBT was limited to 4 hours a day and 120 days a year according to proton beam availability from the National Laboratory for High Energy Physics. Beam lines were also limited to fixed vertical and horizontal beam lines, and patients were immobilized by Styrofoam box manually-hollowed out for individuals. From September 2001, the new hospital-based facility which includes rotational gantries, releases adequate energy proton beams from any direction, using the respiratory gating for 10 patients with pelvic and thoracic disease with the body immobilized using an individually shaped body cast (ESFORM; Engineering System Co., Matsumoto). Patients with head and neck tumors were also immobilized using individually manufactured thermoplastic masks. The treatment is provided 5 days in a week. Respiratory gating was used for the 10 patients with pelvic and thoracic disease. The photon equivalent dose (GyE) was defined as the physical dose (Gy) × the relative biological effectiveness of the proton beam assigned a value of 1.1. Before each treatment, correct placement of the patient relative to the radiation field was confirmed fluoroscopically. The given doses ranged from 19.8 to 45.5 GyE (median: 30.6 GyE) in 11 to 23 fractions. In Japan, the common dose for neuroblastoma with a complete response after chemotherapy is 19.8 Gy, and 10.8 Gy was added for grossly residual disease. In this series, higher doses were administered for patients with recurrent and chemotherapy-resistant disease. Patients underwent a routine physical examination once a week during PBT. After completion of PBT, patients were followed in combination with a pediatrician using CT, MRI, 99mTc bone scans, and 131I- and 123I- metaiodobenzylguanidine scintigrams.

Statistical analysis

Locoregional failure was defined as tumor progression in the anatomic compartment that contained the primary tumor (pelvis, abdomen, thorax, neck). The locoregional control rate was calculated from the start of PBT to the date of local failure in the irradiation field, marginal recurrence, or most recent local progression-free follow up. Statistical analyses were performed using SPSS software (SPSS Inc., Chicago, IL, USA). Acute and late toxicities associated with treatments were evaluated using the National Cancer Institute Common Toxicity Criteria for Adverse Events (CTCAE) version 4.0.

Results

The results for the 14 patients are shown in Table 2. The median follow-up periods from diagnosis and the start of PBT were 40 months (M) (range: 17 M-30 years (Y)) and 21 M (5 M-29 Y), respectively, for all patients, and 46 M (25 M-30 Y) and 30 M (18 M-29 Y), respectively, for surviving patients. The planned irradiation was completed in all patients. At the time of analysis in 2012, 8 patients were alive. Of the 8 patients who received PBT as initial treatment, 6 (75%) were alive with no evidence of disease, 1 was alive with distant metastasis, and 1 had died from tumor progression. Of the 6 patients who received PBT for recurrence, 1 was alive with no evidence of disease and 5 had died from tumor progression. The initial progression sites were bone (n = 2), bone marrow (n = 2), liver (n = 1), brain (n = 1), and lymph nodes (n = 1).
Table 2

Clinical outcomes in 14 patients treated with proton beam therapy

Patient No

Cause of death

Survival after PBT (M)

Progression

Acute toxicity*

Late toxicity*

1

alive

349

none

none

vertebral growth retardation, narrowed aorta

2

alive

61

none

none

none

3

alive

40

none

none

none

4

alive

39

none

temporary hair loss, G1 pharyngitis

None

5

tumor

9

bone

G1 skin reaction

None

6

alive

20

none

None

G1 skin pigmentation

7

alive

20

bone marrow

None

none

8

alive

18

none

hair loss

thin hair

9

tumor

11

brain

G1 skin reaction

none

10

tumor

11

bone

none

none

11

tumor

31

bone marrow

none

none

12

tumor

27

lymph node

none

none

13

tumor

5

liver

none

-

14

alive

22

none

none

none

*G1: Grade 1 according to Criteria for Adverse Events version 3.0 of the National Cancer Institute and the late radiation morbidity scoring scheme of the Radiation Therapy Oncology Study Group/European Organization for Research and Treatment of Cancer.

Recurrence in the treatment field was not observed, but marginal failures occurred in 2 patients (Nos. 12, 13), resulting in a 3-year a locoregional control rate of 82% (CI: 59-100%) (Figure 1). One patient (No. 12) received PBT for a bulky recurrent tumor. This patient received PBT of 19.8 GyE for the pre-chemotherapy tumor volume, 30.6 GyE for the gross tumor volume, and 41.4 GyE for the gross tumor volume excluding the IORT field (Figure 2). The PTV margins were 5 mm because of the large irradiation volume. After completion of PBT, the tumor had disappeared, but paraaortic lymph node metastases appeared below the first irradiation field 17 months after PBT. This recurrent lesion was irradiated with about a 40% dose of 19.8 GyE. The second patient (No. 13) also received PBT for a bulky recurrent tumor invading the hepatic portal region (Figure 3). The irradiation field was too large to add the margin of 1.5 cm, and the whole tumor was included in the treatment field with a margin of 7 mm for the dose of 30.6 GyE, but the left kidney was blocked after 10.8 GyE. The tumor at the Morison fossa was excluded from the treatment field after 30.6 GyE by considering tolerance of the liver, and the treatment field was reduced to the main retroperitoneal tumor. The tumor shrunk in size, but disease progression occurred in the portal region beyond the irradiation field 5 months after PBT.
Figure 1
Figure 1

Local control rate for all patients.

Figure 2
Figure 2

Dose distribution for patient No.12.

Figure 3
Figure 3

Dose distribution for patient No.13.

No severe acute toxicity was observed. A mild skin reaction and mucositis occurred in 3 patients and temporary hair loss in 2 as acute toxicity. Late toxicity was observed in 2 of the 13 patients who were followed up for more than 6 months. One of these patients was a neonatal case with stage 3 disease who reached adulthood. Retrospective measurement of the mitosis-karyorrhexis index (MKI) of pathological samples showed a favorable histology consistent with International Neuroblastoma Pathology Committee (INPC) criteria (low MKI and ≤1 year old at diagnosis). The MYCN status was not measured, but the patient may have been classified into the intermediate risk group with non-amplified MYCN, based on her survival. Thus, for a similar contemporary case, radiotherapy and chemotherapy would have been reduced; however, pathological and biological data for INRG risk grouping were not available in 1982 and she received PBT of 28.6 GyE in 13 fractions to the upper abdomen at age 1 year old. She visited our hospital due to unexplained occasional stomach pain during early pregnancy at 28 years after the PBT. The pain increased after eating, which caused loss of appetite. Thus, the patient did not gain enough weight during pregnancy and this resulted in a premature birth. A CT scan after birth showed vertebral growth retardation and a narrowed aorta, including the celiac artery (Figure 4). The reason for the stomach pain was concluded to be mesenteric ischemia due to stenosis of the superior mesenteric artery. Cilostazol was prescribed to increase blood flow and her stomach pain was relieved. There were no symptoms caused by vertebral growth retardation. The other patient received 19.8 GyE to the skull when he was 2 year old (Figure 5). Hair loss was prolonged, and his hair has been thin with some white hair from 18 months after PBT. No secondary cancer was observed.
Figure 4
Figure 4

CT scan 28 years after the PBT. (A) Growth retardation in the ventral vertebral body. (B) Narrowing of the aorta below the irradiated field.

Figure 5
Figure 5

Proton irradiation of the skull reduces the dose to brain tissue.

Discussion

Recent progress of systemic therapies for advanced neuroblastoma has resulted in improved clinical outcomes, but local control is still an important concern. Panandiker et al. suggested that locoregional tumor control has an influence on overall survival [18], but gross resection is sometimes difficult because of bulky and invasive features involving critical organs. The prognosis of neuroblastoma with gross residual disease is poor and control is difficult, with Kushner et al. finding local recurrence in 3 of 7 patients with residual disease [3]. Neuroblastoma is highly sensitive to radiotherapy and a relatively low radiation dose of approximately 20 Gy is commonly used for minimal residual disease; however, the necessity for an escalated dose for gross residual disease has been suggested [19, 20]. Kogan et al. reported an estimated 5-year locoregional recurrence rate of 51% for high risk primary neuroblastoma treated with 10 Gy for residual disease [19]. Compared with this, local recurrence was not observed in the patients with primary disease in our study, even though most patients had gross residual disease that was considered to be difficult to control by photon radiotherapy.

Recurrent neuroblastoma is also difficult to control, and sometimes acquires resistance to chemotherapy. Local radiotherapy for recurrent neuroblastoma has not been established. In our cases, most recurrent tumors were too large to be treated by photon radiotherapy, but around 20 Gy seemed to be insufficient for these tumors. Therefore, we treated 6 patients with recurrent disease using PBT with escalated doses from 30.6 to 45.5 GyE. Most of the patients eventually died, but 5 of the 6 had had an immediate complete response, with 2 surviving for more than 2 years after PBT and 1 patient still alive with no evidence of recurrence. These results suggest that PBT may contribute to improvement of the prognosis of patients with recurrent disease.

PBT is considered to be superior to intensity modulated radiation therapy (IMRT) for pediatric patients because higher doses can be delivered homogeneously to a large volume of neuroblastoma with a small number of ports while delivering very low doses in the path of the beam, which minimize the risk of a secondary cancer due to peripheral doses [10, 12]. Hillbrand et al. suggested that PBT for pelvic neuroblastoma was preferred over IMRT because the dose distribution in IMRT produced a 1.5-fold greater risk of adverse events compared to PBT [10]. However, it is still important to monitor possible toxicity after PBT and we experienced late toxicities in 2 patients. Follow-up is particularly important for girls for whom the aorta was included in the treatment field in PBT and photon radiotherapy because this may affect a future pregnancy. The threshold of aortic retardation is unclear; therefore, irradiation of the aorta should be avoided as much as possible by taking advantage of the proton dose distribution. Thus, the indication for PBT and photon radiotherapy in infancy should be carefully considered. Hair loss is generally only a minor problem after photon radiotherapy at 20 Gy, but this effect was prolonged in one of our patients. This may be because proton beams do not have a build-up effect and doses at the skin surface are higher than those in photon radiotherapy when the target is located near the surface. We choose proton as an alternative to electron beams to reduce cranial doses, but hair follicles are located 4 mm deep in the skin and the lethal dose for hair follicles is 16 Gy [21]. This indicates that the treatment field and indication should be carefully determined to optimize the utilization of the characteristics of proton beams.

Until recently, PBT was viewed as a novel therapy, and therefore we had mainly used PBT to treat patients with neuroblastoma that was difficult to manage, with most of these patients having gross residual disease. Management with photon radiotherapy was difficult in 8 of the 14 patients in the study and PBT was chosen as a potential treatment option. The outcomes in these cases were favorable and little severe toxicity occurred, even though higher doses (> 20 Gy) were used for some patients. Our study is limited by the small number of patients and restriction of long-term follow-up to only one patient, but the results suggested that PBT may be conducted safely for patients with neuroblastoma that is difficult to manage using photon beams.

Conclusions

PBT may be conducted safely for patients with neuroblastoma that is difficult to manage using photon beams.

Abbreviations

PBT: 

Proton beam therapy

INSS: 

International Neuroblastoma Staging System

INRG: 

The international neuroblastoma risk group

IORT: 

Intraoperative radiotherapy

CTV: 

Clinical target volume

PTV: 

Planning target volume

MKI: 

Mitosis-karyorrhexis index

INPC: 

International Neuroblastoma Pathology Committee

IMRT: 

Intensity modulated radiation therapy.

Declarations

Acknowledgment

This work was supported by the “Funding Program for World-Leading Innovative R&D on Science and Technology (FIRST Program)”, initiated by the Council for Science and Technology Policy (CSTP).

Authors’ Affiliations

(1)
Department of Radiation Oncology, University of Tsukuba, Tennodai 1-1-1, Tsukuba, Ibaraki, Japan
(2)
Department of Pediatrics, University of Tsukuba, Tsukuba, Ibaraki, Japan
(3)
Department of Pediatric Surgery, University of Tsukuba, Tsukuba, Ibaraki, Japan
(4)
Department of Radiation OncologY, Tokyo Medical University Ibaraki Medical Center, Ami, Inashiki, Ibaraki, Japan

References

  1. Berthold F, Boos J, Burdach S, Erttmann R, Henze G, Hermann J, Klingebiel T, Kremens B, Schilling FH, Schrappe M, et al.: Myeloablative megatherapy with autologous stem-cell rescue versus oral maintenance chemotherapy as consolidation treatment in patients with high-risk neuroblastoma: a randomised controlled trial. Lancet Oncol 2005, 6: 649-658. 10.1016/S1470-2045(05)70291-6View ArticlePubMedGoogle Scholar
  2. Kaneko M, Tsuchida Y, Mugishima H, Ohnuma N, Yamamoto K, Kawa K, Iwafuchi M, Sawada T, Suita S: Intensified chemotherapy increases the survival rates in patients with stage 4 neuroblastoma with MYCN amplification. J Pediatr Hematol Oncol 2002, 24: 613-621. 10.1097/00043426-200211000-00004View ArticlePubMedGoogle Scholar
  3. Kushner BH, Wolden S, LaQuaglia MP, Kramer K, Verbel D, Heller G, Cheung NK: Hyperfractionated low-dose radiotherapy for high-risk neuroblastoma after intensive chemotherapy and surgery. J Clin Oncol 2001, 19: 2821-2828.PubMedGoogle Scholar
  4. Matthay KK, Villablanca JG, Seeger RC, Stram DO, Harris RE, Ramsay NK, Swift P, Shimada H, Black CT, Brodeur GM, et al.: Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children’s Cancer Group. N Engl J Med 1999, 341: 1165-1173. 10.1056/NEJM199910143411601View ArticlePubMedGoogle Scholar
  5. La Quaglia MP, Kushner BH, Heller G, Bonilla MA, Lindsley KL, Cheung NK: Stage 4 neuroblastoma diagnosed at more than 1 year of age: gross total resection and clinical outcome. J Pediatr Surg 1994, 29: 1162-1165. discussion 1165–1166 10.1016/0022-3468(94)90301-8View ArticlePubMedGoogle Scholar
  6. Simon T, Berthold F, Borkhardt A, Kremens B, De Carolis B, Hero B: Treatment and outcomes of patients with relapsed, high-risk neuroblastoma: results of German trials. Pediatr Blood Cancer 2011, 56: 578-583. 10.1002/pbc.22693View ArticlePubMedGoogle Scholar
  7. Garaventa A, Parodi S, De Bernardi B, Dau D, Manzitti C, Conte M, Casale F, Viscardi E, Bianchi M, D’Angelo P, et al.: Outcome of children with neuroblastoma after progression or relapse. A retrospective study of the Italian neuroblastoma registry. Eur J Cancer 2009, 45: 2835-2842. 10.1016/j.ejca.2009.06.010View ArticlePubMedGoogle Scholar
  8. Rich BS, McEvoy MP, LaQuaglia MP, Wolden SL: Local control, survival, and operative morbidity and mortality after re-resection, and intraoperative radiation therapy for recurrent or persistent primary high-risk neuroblastoma. J Pediatr Surg 2011, 46: 97-102. 10.1016/j.jpedsurg.2010.09.068View ArticlePubMedGoogle Scholar
  9. Athar BS, Paganetti H: Comparison of second cancer risk due to out-of-field doses from 6-MV IMRT and proton therapy based on 6 pediatric patient treatment plans. Radiother Oncol 2011, 98: 87-92. 10.1016/j.radonc.2010.11.003View ArticlePubMedPubMed CentralGoogle Scholar
  10. Hillbrand M, Georg D, Gadner H, Potter R, Dieckmann K: Abdominal cancer during early childhood: a dosimetric comparison of proton beams to standard and advanced photon radiotherapy. Radiother Oncol 2008, 89: 141-149. 10.1016/j.radonc.2008.06.012View ArticlePubMedGoogle Scholar
  11. Kozak KR, Adams J, Krejcarek SJ, Tarbell NJ, Yock TI: A dosimetric comparison of proton and intensity-modulated photon radiotherapy for pediatric parameningeal rhabdomyosarcomas. Int J Radiat Oncol Biol Phys 2009, 74: 179-186. 10.1016/j.ijrobp.2008.06.1942View ArticlePubMedGoogle Scholar
  12. Heinzelmann F, Thorwarth D, Lamprecht U, Kaulich TW, Fuchs J, Seitz G, Ebinger M, Handgretinger R, Bamberg M, Weinmann M: Comparison of different adjuvant radiotherapy approaches in childhood bladder/prostate rhabdomyosarcoma treated with conservative surgery. Strahlenther Onkol 2011, 187: 715-721. 10.1007/s00066-011-2261-3View ArticlePubMedGoogle Scholar
  13. Lorentini S, Amichetti M, Spiazzi L, Tonoli S, Magrini SM, Fellin F, Schwarz M: Adjuvant intensity-modulated proton therapy in malignant pleural mesothelioma. A comparison with intensity-modulated radiotherapy and a spot size variation assessment. Strahlenther Onkol 2012, 188: 216-225. 10.1007/s00066-011-0038-3View ArticlePubMedGoogle Scholar
  14. Hattangadi JA, Rombi B, Yock TI, Broussard G, Friedmann AM, Huang M, Chen YL, Lu HM, Kooy H, Macdonald SM: Proton radiotherapy for high-risk pediatric neuroblastoma: early outcomes and dose comparison. Int J Radiat Oncol Biol Phys 2012, 83: 1015-1022. 10.1016/j.ijrobp.2011.08.035View ArticlePubMedGoogle Scholar
  15. Monclair T, Brodeur GM, Ambros PF, Brisse HJ, Cecchetto G, Holmes K, Kaneko M, London WB, Matthay KK, Nuchtern JG, et al.: The International Neuroblastoma Risk Group (INRG) staging system: an INRG Task Force report. J Clin Oncol 2009, 27: 298-303. 10.1200/JCO.2008.16.6876View ArticlePubMedPubMed CentralGoogle Scholar
  16. Tsunashima Y, Sakae T, Shioyama Y, Kagei K, Terunuma T, Nohtomi A, Akine Y: Correlation between the respiratory waveform measured using a respiratory sensor and 3D tumor motion in gated radiotherapy. Int J Radiat Oncol Biol Phys 2004, 60: 951-958.View ArticlePubMedGoogle Scholar
  17. Oshiro Y, Okumura T, Ishida M, Sugahara S, Mizumoto M, Hashimoto T, Yasuoka K, Tsuboi K, Sakae T, Sakurai H: Displacement of hepatic tumor at time to exposure in end-expiratory-triggered-pulse proton therapy. Radiother Oncol 2011, 99: 124-130. 10.1016/j.radonc.2011.05.009View ArticlePubMedGoogle Scholar
  18. Pai Panandiker AS, McGregor L, Krasin MJ, Wu S, Xiong X, Merchant TE: Locoregional tumor progression after radiation therapy influences overall survival in pediatric patients with neuroblastoma. Int J Radiat Oncol Biol Phys 2010, 76: 1161-1165. 10.1016/j.ijrobp.2009.03.068View ArticlePubMedPubMed CentralGoogle Scholar
  19. Haas-Kogan DA, Swift PS, Selch M, Haase GM, Seeger RC, Gerbing RB, Stram DO, Matthay KK: Impact of radiotherapy for high-risk neuroblastoma: a Children’s Cancer Group study. Int J Radiat Oncol Biol Phys 2003, 56: 28-39. 10.1016/S0360-3016(02)04506-6View ArticlePubMedGoogle Scholar
  20. Kremens B, Klingebiel T, Herrmann F, Bender-Gotze C, Burdach S, Ebell W, Friedrich W, Koscielniak E, Schmid H, Siegert W, et al.: High-dose consolidation with local radiation and bone marrow rescue in patients with advanced neuroblastoma. Med Pediatr Oncol 1994, 23: 470-475. 10.1002/mpo.2950230604View ArticlePubMedGoogle Scholar
  21. Severs GA, Griffin T, Werner-Wasik M: Cicatricial alopecia secondary to radiation therapy: case report and review of the literature. Cutis 2008, 81: 147-153.PubMedGoogle Scholar

Copyright

© Oshiro et al.; licensee BioMed Central Ltd. 2013

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Comments

By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate. Please note that comments may be removed without notice if they are flagged by another user or do not comply with our community guidelines.

Advertisement

Radiation Oncology

ISSN: 1748-717X

Contact us